Literature DB >> 25987207

Thyroid hormone level is associated with motor symptoms in de novo Parkinson's disease.

Tadashi Umehara1, Hiromasa Matsuno, Chizuko Toyoda, Hisayoshi Oka.   

Abstract

Sympathetic denervation has been observed not only in the myocardium but also in the thyroid of patients with Parkinson's disease (PD). We investigated whether sympathetic denervation as indicated by decreased cardiac (123)I-meta-iodobenzylguanidine uptake is associated with the levels of thyroid hormones and whether the levels of thyroid hormones affect clinical manifestations in patients with PD. The subjects were 75 patients with de novo PD and 20 age-matched healthy controls. We examined the levels of thyroid-stimulating hormone, free triiodothyronine, and free thyroxine, and evaluated the associations of these levels with cardiac (123)I-meta-iodobenzylguanidine uptake and motor symptoms. The results showed that the free triiodothyronine level was below the normal range in 29 patients (approximately 40 %) and was significantly lower in the patients with PD than in the controls. The decreased free triiodothyronine level was associated with akinetic-rigid motor subtype and washout ratio of cardiac (123)I-meta-iodobenzylguanidine scintigraphy. The free triiodothyronine level negatively correlated with disease severity. Thyroid-stimulating hormone level was within normal range. However, its level was lower in patients with tremor-dominant type or mixed type than in those with akinetic-rigid type. All correlations of these variables with the levels of thyroid hormones remained statistically significant on multiple regression analysis. Our results suggest that the thyroid hormone level, especially the free triiodothyronine level, is closely related to motor symptoms in patients with de novo PD. Further studies are needed to clarify whether the decreased hormone levels have functional roles in motor and non-motor symptoms.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25987207     DOI: 10.1007/s00415-015-7780-x

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  34 in total

1.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

2.  Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease.

Authors:  Kelly Del Tredici; Christopher H Hawkes; Estifanos Ghebremedhin; Heiko Braak
Journal:  Acta Neuropathol       Date:  2010-03-14       Impact factor: 17.088

3.  (123)I-metaiodobenzylguanidine myocardial scintigraphy in Parkinson's disease.

Authors:  S Orimo; E Ozawa; S Nakade; T Sugimoto; H Mizusawa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-08       Impact factor: 10.154

4.  Myocardial adrenergic nervous activity is intensified in patients with heart failure without left ventricular volume or pressure overload.

Authors:  Y Imamura; H Ando; T Ashihara; T Fukuyama
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

5.  Differences in nigro-striatal impairment in clinical variants of early Parkinson's disease: evidence from a FP-CIT SPECT study.

Authors:  C Rossi; D Frosini; D Volterrani; P De Feo; E Unti; V Nicoletti; L Kiferle; U Bonuccelli; R Ceravolo
Journal:  Eur J Neurol       Date:  2009-12-29       Impact factor: 6.089

6.  Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans.

Authors:  J C Schilling; W S Adamus; R Palluk
Journal:  Clin Pharmacol Ther       Date:  1992-05       Impact factor: 6.875

7.  Thyroid function in Parkinson disease.

Authors:  J R Berger; R E Kelley
Journal:  Neurology       Date:  1981-01       Impact factor: 9.910

Review 8.  Thyroid-adrenergic interactions: physiological and clinical implications.

Authors:  J Enrique Silva; Suzy D C Bianco
Journal:  Thyroid       Date:  2008-02       Impact factor: 6.568

9.  Possible involvement of nigrostriatal dopamine system in the inhibition of thyrotropin secretion in the rat.

Authors:  P Männistö; J Mattila; S Kaakkola
Journal:  Eur J Pharmacol       Date:  1981-12-17       Impact factor: 4.432

10.  The hypothalamic-pituitary-thyroid axis in subjects with subclinical thyroid diseases: the impact of the negative feedback mechanism.

Authors:  Paolo Falaschi; Antonio Martocchia; Antonella Proietti; Rosaria D'Urso; Serena Gargano; Franco Culasso; Antonio Rocco
Journal:  Neuro Endocrinol Lett       Date:  2004-08       Impact factor: 0.765

View more
  7 in total

Review 1.  Shedding light on thyroid hormone disorders and Parkinson disease pathology: mechanisms and risk factors.

Authors:  S Mohammadi; M Dolatshahi; F Rahmani
Journal:  J Endocrinol Invest       Date:  2020-06-04       Impact factor: 4.256

Review 2.  Relationship between thyroid hormones and central nervous system metabolism in physiological and pathological conditions.

Authors:  Nadia Sawicka-Gutaj; Natalia Zawalna; Paweł Gut; Marek Ruchała
Journal:  Pharmacol Rep       Date:  2022-06-30       Impact factor: 3.919

3.  The prediction effects of thyroid function in the severity of Guillain-Barré syndrome.

Authors:  Lingxin Kong; Xiujuan Wu; Yanwei Cheng; Shan Liu; Kangding Liu; Chunrong Li
Journal:  Neurol Sci       Date:  2022-04-26       Impact factor: 3.830

4.  TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone.

Authors:  Cong Zheng; Guiqin Chen; Yang Tan; Weiqi Zeng; Qiwei Peng; Ji Wang; Chi Cheng; Xiaoman Yang; Shuke Nie; Yan Xu; Zhentao Zhang; Stella M Papa; Keqiang Ye; Xuebing Cao
Journal:  Front Cell Neurosci       Date:  2018-12-20       Impact factor: 5.505

5.  Genetic correlation between thyroid hormones and Parkinson's disease.

Authors:  Jiyi Xu; Cheng Zhao; Ye Liu; Congjie Xu; Bin Qin; Hui Liang
Journal:  Clin Exp Immunol       Date:  2022-06-23       Impact factor: 5.732

6.  Selenotranscriptomic Analyses Identify Signature Selenoproteins in Brain Regions in a Mouse Model of Parkinson's Disease.

Authors:  Xiong Zhang; Yang-Lie Ye; Hui Zhu; Sheng-Nan Sun; Jing Zheng; Hui-Hui Fan; Hong-Mei Wu; Song-Fang Chen; Wen-Hsing Cheng; Jian-Hong Zhu
Journal:  PLoS One       Date:  2016-09-22       Impact factor: 3.240

Review 7.  Role and Mechanism of Vitamin A Metabolism in the Pathophysiology of Parkinson's Disease.

Authors:  Anaıs Marie; Morgane Darricau; Katia Touyarot; Louise C Parr-Brownlie; Clémentine Bosch-Bouju
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.